Efficacy of immune checkpoint inhibitors alone or in combination with chemotherapy in NSCLC harboring ERBB2 mutations
Introduction - In contrast to other driver mutations, no targeted therapies have yet been approved in ERBB2-mutated NSCLC (HER2mu NSCLC). Nevertheless, several compounds have revealed promising early efficacy data, which need to be evaluated in the context of current standard approaches. Although da...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
8 July 2021
|
| In: |
Journal of thoracic oncology
Year: 2021, Jahrgang: 16, Heft: 11, Pages: 1952-1958 |
| ISSN: | 1556-1380 |
| DOI: | 10.1016/j.jtho.2021.06.025 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.jtho.2021.06.025 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S1556086421022929 |
| Verfasserangaben: | Felix C. Saalfeld, Carina Wenzel, Petros Christopoulos, Sabine Merkelbach-Bruse, Timm M. Reissig, Silke Laßmann, Sebastian Thiel, Jan A. Stratmann, Ralf Marienfeld, Johannes Berger, Alexander Desuki, Janna-Lisa Velthaus, Diego Kauffmann-Guerrero, Albrecht Stenzinger, Sebastian Michels, Thomas Herold, Michael Kramer, Sylvia Herold, Amanda Tufman, Sonja Loges, Jürgen Alt, Maria Joosten, Gerlinde Schmidtke-Schrezenmeier, Martin Sebastian, Susann Stephan-Falkenau, Cornelius F. Waller, Marcel Wiesweg, Jürgen Wolf, Michael Thomas, Daniela E. Aust, Martin Wermke |
Search Result 1